Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
54569-6607-00 54569-6607 Dutasteride Avodart 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 10, 2002 In Use
68788-9044-09 68788-9044 Dutasteride Avodart Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 10, 2002 Nov 30, 2013 No Longer Used
68788-9044-03 68788-9044 Dutasteride Avodart Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec 10, 2002 Nov 30, 2013 No Longer Used
50242-0061-01 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Feb 26, 2004 In Use
50242-0060-10 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 1, 2019 Jan 31, 2023 In Use
50242-0061-10 50242-0061 Bevacizumab Avastin 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 1, 2019 Feb 28, 2023 In Use
50242-0060-01 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Feb 26, 2004 In Use
00003-4160-14 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
00003-4040-12 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4040-60 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4160-60 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
72694-0515-01 72694-0515 Calaspargase Pegol Asparlas 750.0 U/mL Chemotherapy Miscellaneous Agent Enzyme Intravenous Sep 27, 2019 In Use
00078-0669-13 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 In Use
00078-0669-61 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 In Use
00078-0690-61 00078-0690 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 In Use
00078-0669-84 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 Feb 1, 2016 In Use
00173-0808-01 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
00173-0821-01 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 22, 2011 Aug 31, 2017 No Longer Used
00173-0821-02 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 22, 2011 Aug 31, 2017 No Longer Used
00173-0821-33 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 22, 2011 Aug 31, 2017 No Longer Used
00173-0808-05 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
00173-0808-02 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
72205-0171-07 72205-0171 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb 6, 2024 In Use
55150-0366-10 55150-0366 ARSENIC TRIOXIDE ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Oct 15, 2021 In Use
63323-0637-10 63323-0637 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Aug 31, 2018 In Use

Found 11120 results — Export these results